Table 4.

Distribution of number of patients with pairwise classification assignments by sample set for all pairs of the four tests.

Test 1	Test 2	Melanoma Development set			Lung Cancer Development Set			PSEA Reference Set
	BDX008	BDX008+	BDX008–	Total	BDX008+	BDX008–	Total	BDX008+	BDX008–	Total
ICB	Sensitive	34	0	34	18	0	18	24	0	24
	Resistant	38	47	85	27	71	98	19	57	76
	Total	72	47	119	45	71	116	43	57	100
	BDX008	BDX008+	BDX008–	Total	BDX008+	BDX008–	Total	BDX008+	BDX008–	Total
PIR	NotResist	64	4	68	43	32	75	42	28	70
	Resistant	8	43	51	2	39	41	1	29	30
	Total	72	47	119	45	71	116	43	57	100
	BDX008	BDX008+	BDX008–	Total	BDX008+	BDX008–	Total	BDX008+	BDX008–	Total
VeriStrat	VS Good	72	0	72	45	0	45	43	35	78
	VS Poor	26	21	47	43	28	71	0	22	22
	Total	98	21	119	88	28	116	43	57	100
	ICB	Sensitive	Resistant	Total	Sensitive	Resistant	Total	Sensitive	Resistant	Total
PIR	NotResist	34	34	68	18	57	75	23	47	70
	Resistant	0	51	51	0	41	41	1	29	30
	Total	34	85	119	18	98	116	24	76	100
	ICB	Sensitive	Resistant	Total	Sensitive	Resistant	Total	Sensitive	Resistant	Total
VeriStrat	VS Good	34	64	98	18	70	88	24	54	78
	VS Poor	0	21	21	0	28	28	0	22	22
	Total	34	85	119	18	98	116	24	76	100
	VeriStrat	VS Good	VS Poor	Total	VS Good	VS Poor	Total	VS Good	VS Poor	Total
PIR	NotResist	68	0	68	56	3	59	64	6	70
	Resistant	30	21	51	32	25	57	14	16	30
	Total	98	21	119	88	28	116	78	22	100

NotResist: Not Resistant.